Splice Ablation Kinase Inhibition (SAKI) of Receptor Tyrosine Kinases
Abstract
This final report describes the progress made towards the use of antisense oligonucleotides (ASOs) as a tool to drive splicing-based inhibition of the Epidermal Growth Factor Receptor (EGFR). Through this project we have confirmed the ability of EGFR-directed ASOs to inhibit EGFR signaling, decrease proliferation and survival, and drive a program of proteomic expression that mirrors that caused by erlotinib. Further more, we showed that the ASO-based approach works in both tyrosine kinase resistant and sensitive cell models, and to a less extent in wild type, EGFR-overexpressing lung cancer cell line models. This work was published in the journal of Nucleic Acid Therapeutics (Impact factor 4.2).
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2022
- Accession Number
- AD1207380
Entities
People
- Timothy J Robinson
Organizations
- H. Lee Moffitt Cancer Center & Research Institute